SAN DIEGO, March 21, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (4875), today announced it has completed enrollment in its Phase 2 clinical trial (MN-221-CL-007) evaluating the safety and efficacy of MN-221 for treatment of acute exacerbations of asthma. Patients suffering from acute exacerbations of asthma in the emergency room who were not promptly responding to standard pharmacotherapy were enrolled in the study. MediciNova is currently in the process of auditing and organizing the data and preparing to lock the database for a complete analysis. MediciNova anticipates releasing preliminary results in the second quarter of 2012.
